Cargando…

Evaluation of the systemic and mucosal immune response induced by COVID-19 and the BNT162b2 mRNA vaccine for SARS-CoV-2

BACKGROUND: The currently used SARS-CoV-2 mRNA vaccines have proven to induce a strong and protective immune response. However, functional relevance of vaccine-generated antibodies and their temporal progression are still poorly understood. Thus, the central aim of this study is to gain a better und...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nickel, Olaf, Rockstroh, Alexandra, Wolf, Johannes, Landgraf, Susann, Kalbitz, Sven, Kellner, Nils, Borte, Michael, Pietsch, Corinna, Fertey, Jasmin, Lübbert, Christoph, Ulbert, Sebastian, Borte, Stephan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9578597/ https://www.ncbi.nlm.nih.gov/pubmed/36256664 http://dx.doi.org/10.1371/journal.pone.0263861

Ejemplares similares

Correlation of humoral immune responses to different SARS-CoV-2 antigens with virus neutralizing antibodies and symptomatic severity in a German COVID-19 cohort
por: Rockstroh, Alexandra, et al.
Publicado: (2021)

Comparison of pre-analytical characteristics for molecular and serological diagnostics of COVID-19
por: Wendt, Ralph, et al.
Publicado: (2021)

Comprehensive investigation of an in-hospital transmission cluster of a symptomatic SARS-CoV-2–positive physician among patients and healthcare workers in Germany
por: Wendt, Ralph, et al.
Publicado: (2020)

Evaluation of Simple Lateral Flow Immunoassays for Detection of SARS-CoV-2 Neutralizing Antibodies
por: Nickel, Olaf, et al.
Publicado: (2022)

Differences of SARS-CoV-2 serological test performance between hospitalized and outpatient COVID-19 cases
por: Wolf, Johannes, et al.
Publicado: (2020)

Impfungen
por: Wendt, Sebastian, et al.
Publicado: (2021)

Bacterial contamination of the smartphones of healthcare workers in a German tertiary-care hospital before and during the COVID-19 pandemic
por: Tannhäuser, Romy, et al.
Publicado: (2022)

A Recombinant Zika Virus Envelope Protein with Mutations in the Conserved Fusion Loop Leads to Reduced Antibody Cross-Reactivity upon Vaccination
por: Berneck, Beatrice Sarah, et al.
Publicado: (2020)

Immunization with different recombinant West Nile virus envelope proteins induces varying levels of serological cross-reactivity and protection from infection
por: Weiß, Rebecca, et al.
Publicado: (2023)

COVID-19 treatment strategies with drugs centrally procured by the German Federal Ministry of Health in a representative tertiary care hospital: a temporal analysis
por: Marx, Kathrin, et al.
Publicado: (2023)

Mucosal immune response in BNT162b2 COVID-19 vaccine recipients
por: Azzi, Lorenzo, et al.
Publicado: (2021)

Mucosal immune response after the booster dose of the BNT162b2 COVID-19 vaccine
por: Azzi, Lorenzo, et al.
Publicado: (2023)

Point-of-care bulk testing for SARS-CoV-2 by combining hybridization capture with improved colorimetric LAMP
por: Bokelmann, Lukas, et al.
Publicado: (2021)

Low-Energy Electron Irradiation of Tick-Borne Encephalitis Virus Provides a Protective Inactivated Vaccine
por: Finkensieper, Julia, et al.
Publicado: (2022)

Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
por: Reiter, Rieke, et al.
Publicado: (2022)

Clinical outcomes of hospitalized COVID-19 patients treated with remdesivir: a retrospective analysis of a large tertiary care center in Germany
por: Marx, Kathrin, et al.
Publicado: (2022)

BNT162b2 vaccine induces antibody release in saliva: a possible role for mucosal viral protection?
por: Darwich, Abbass, et al.
Publicado: (2022)

Longitudinal Analysis of SARS-CoV-2-Specific Cellular and Humoral Immune Responses and Breakthrough Infection following BNT162b2/BNT162b2/BNT162b2 and ChAdOx1/ChAdOx1/BNT162b2 Vaccination: A Prospective Cohort in Naive Healthcare Workers
por: Ko, Geon Young, et al.
Publicado: (2023)

Neutralizing Activity of BNT162b2-Elicited Serum
por: Liu, Yang, et al.
Publicado: (2021)

BNT162b2 vaccine for prevention of COVID-19
Publicado: (2021)

Boosting BNT162b2 vaccine efficacy in CLL
por: Bhat, Seema A., et al.
Publicado: (2022)

Erythema Multiforme after BNT162b2 Vaccination
por: Katayama, Sho, et al.
Publicado: (2022)

Importance of nasal secretions in the evaluation of mucosal immunity elicited by mRNA BNT162b2 COVID-19 Vaccine
por: Francavilla, Beatrice, et al.
Publicado: (2022)

Pseudo-Anaphylactic Reactions to Pfizer BNT162b2 Vaccine: Report of 3 Cases of Anaphylaxis Post Pfizer BNT162b2 Vaccination
por: Lim, Xin Rong, et al.
Publicado: (2021)

Evaluation of the Effectiveness of BNT162b2 Primary Vaccination and Booster Dose to SARS-CoV-2 in Eliciting Stable Mucosal Immunity
por: Lambiase, Alessandro, et al.
Publicado: (2022)

Immune Cellular Evaluation Following Newborn Screening For Severe T and B Cell Lymphopenia
por: Wolf, Johannes, et al.
Publicado: (2019)

Delayed Antibody and T-Cell Response to BNT162b2 Vaccination in the Elderly, Germany
por: Schwarz, Tatjana, et al.
Publicado: (2021)

Pfizer SARS-CoV-2 BNT162b2 mRNA vaccination (BNT162b2) has no adverse effect on elective oocyte cryopreservation outcomes
por: Karavani, Gilad, et al.
Publicado: (2022)

Immune Responses After Vaccination With Primary 2-Dose ChAdOx1 Plus a Booster of BNT162b2 or Vaccination With Primary 2-Dose BNT162b2 Plus a Booster of BNT162b2 and the Occurrence of Omicron Breakthrough Infection
por: Choi, Seong-Ho, et al.
Publicado: (2023)

Waning Immunity after the BNT162b2 Vaccine in Israel
por: Goldberg, Yair, et al.
Publicado: (2021)

Myocarditis after BNT162b2 Vaccination in Israeli Adolescents
por: Mevorach, Dror, et al.
Publicado: (2022)

Acute interstitial nephritis after vaccination with BNT162b2
por: Rieckmann, Sonja, et al.
Publicado: (2022)

Effectiveness of BNT162b2 against COVID-19 in adolescents
por: Powell, Annabel A, et al.
Publicado: (2022)

Acute myocarditis following administration of BNT162b2 vaccine
por: Habib, Mhd Baraa, et al.
Publicado: (2021)

Beyond neutralization for BNT162b2 mRNA vaccination
por: Damani-Yokota, Payal, et al.
Publicado: (2021)

Myocarditis after BNT162b2 Vaccination in Israeli Adolescents
por: Witberg, Guy, et al.
Publicado: (2022)

Systemic and Mucosal Humoral Immune Response Induced by Three Doses of the BNT162b2 SARS-CoV-2 mRNA Vaccines
por: Mancuso, Roberta, et al.
Publicado: (2022)

Évaluation de l'immunogénicité après vaccination COVID-19 hétérologue ChAdOx1-nCoV19/BNT162b2 et homologue BNT162b2/BNT162b2– Cohorte ANRS0001S COV-POPART
por: Lachâtre, M., et al.
Publicado: (2022)

CIAS1-associated autoinflammatory syndrome first diagnosed at age 48 years: a case report
por: Fasshauer, M, et al.
Publicado: (2015)

Long-term immunogenicity of BNT162b2 vaccination in older people and younger health-care workers
por: Tober-Lau, Pinkus, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9kmurseqbeob0lr0jc74tr721e